carmustine + floxuridine + mitomycin C

This is a combination chemotherapy regimen consisting of three agents—carmustine (also known as BCNU), floxuridine (FUDR), and mitomycin C (MMC)—used primarily for the treatment of hepatic metastases from colorectal cancer. Each component has a distinct mechanism of action: - Carmustine is an alkylating agent that cross-links DNA, inhibiting DNA replication and transcription. - Floxuridine is an antimetabolite that disrupts DNA synthesis by mimicking pyrimidines, leading to inhibition of thymidylate synthase after conversion to fluorouracil. - Mitomycin C is an antitumor antibiotic with alkylating properties; it cross-links DNA strands, thereby inhibiting both DNA synthesis and function. The combination has been used via intrahepatic arterial infusion or bolus administration in patients with unresectable liver metastases from colorectal cancer. Clinical studies have shown response rates ranging from approximately 50% to over 70%, including in patients previously treated with systemic chemotherapy. Toxicities include gastrointestinal side effects such as diarrhea and nausea/vomiting, as well as hepatic toxicity[1][2].

Other names

carmustine and floxuridine and mitomycin CBCNU + FUDR + MMC